Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787068 | 1.00 | FYN (0.46) | FYNCHEK1PARP10PARP11BRD4 | |
| SCHEMBL6784586 | 0.88 | SLC6A2 (0.36) | FYNCHEK1BRD4CREBBPCHRM1 | |
| SCHEMBL6784584 | 0.88 | SLC6A2 (0.36) | FYNCHEK1BRD4CREBBPCHRM1 | |
| SCHEMBL6790502 | 0.82 | HTR2C (0.41) | CHRM1CHRM3 | |
| SCHEMBL6790499 | 0.82 | HTR2C (0.41) | CHRM1CHRM3 | |
| SCHEMBL6790774 | 0.81 | BRD4 (0.40) | BRD4CREBBPCHRM1CHRM3SLC6A2 | |
| SCHEMBL6790777 | 0.81 | BRD4 (0.40) | BRD4CREBBPCHRM1CHRM3SLC6A2 | |
| SCHEMBL6782255 | 0.80 | PLAT (0.39) | CHRM1CHRM3SLC6A2SLC6A4 | |
| SCHEMBL6782257 | 0.80 | PLAT (0.39) | CHRM1CHRM3SLC6A2SLC6A4 | |
| Fumaric Acid SCHEMBL6782504 | 0.79 | HRH1 (0.39) | CHRM1CHRM3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | disclosed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | FYN 1257/4885CHEK1 4335/4885PARP10 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.